Latest Biotechnology News

Page 11 of 80
Actinogen Medical’s pivotal XanaMIA trial for Alzheimer’s disease has received a green light from its independent Data Monitoring Committee to continue, reinforcing confidence in the drug’s safety and efficacy profile.
Ada Torres
Ada Torres
30 Jan 2026
Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.
Ada Torres
Ada Torres
30 Jan 2026
Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.
Ada Torres
Ada Torres
30 Jan 2026
Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.
Ada Torres
Ada Torres
30 Jan 2026
Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.
Ada Torres
Ada Torres
30 Jan 2026
Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.
Ada Torres
Ada Torres
30 Jan 2026
Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.
Ada Torres
Ada Torres
30 Jan 2026
Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.
Ada Torres
Ada Torres
30 Jan 2026
Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.
Ada Torres
Ada Torres
30 Jan 2026
Percheron Therapeutics has reported encouraging safety and efficacy signals from its HMBD-002 phase I trial, and outlined an innovative modular phase II trial design targeting multiple cancers in 2026.
Ada Torres
Ada Torres
30 Jan 2026
Nanollose has advanced its largest pilot production of Nullarbor™ fibre, integrating a refined microbial cellulose process that promises easier adoption by textile manufacturers. The company also bolstered its intellectual property portfolio and secured additional funding post-quarter.
Maxwell Dee
Maxwell Dee
30 Jan 2026
Anatara Lifesciences reports encouraging interim pre-clinical results for its Anti-Obesity Project, with a candidate compound showing significant effects on weight regain and visceral fat in mice. The company also completed a $1.2 million capital raise, bolstering its financial position as it advances research.
Ada Torres
Ada Torres
30 Jan 2026